Companies › Debiopharm International
8 active drug programs in 10 registered trials: 8 Phase 1, 2 Phase 3; Oncology, Metabolic and endocrine, Other, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Debio 4326 GnRH receptor agonist | GNRH1 | Phase 3 | Central Precocious Puberty | Feb 2028 |
| Debio 4126 somatostatin analog (somatostatin receptor agonist) | SSTR2, SSTR5 | Phase 3 | Acromegaly | Jun 2028 |
| Debio 1453P | – | Phase 1 | Healthy Participants | Nov 2026 |
| Afabicin Enoyl-[acyl-carrier-protein] reductase (FabI) inhibitor | – | Phase 1 | Renal Impairment | Dec 2027 |
| Lunresertib PKMYT1 inhibitor | PKMYT1 | Phase 1 | Advanced Solid Tumor | Dec 2027 |
| RP-3500 ATR inhibitor | ATR | Phase 1 | Advanced Solid Tumor; Solid Tumor | Dec 2027 |
| Zedoresertib (Debio 0123) | – | Phase 1 | Advanced Solid Tumor; Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Dec 2027 |
| Debio 1562M | – | Phase 1 | Acute Myeloid Leukemia | Nov 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05566574 | RP-3500 | Phase 1 | Solid Tumor | Oncology | Sep 2026 |
| NCT07035769 | Debio 1453P | Phase 1 | Healthy Participants | Other | Nov 2026 |
| NCT07758608 | Afabicin | Phase 1 | Renal Impairment | Genitourinary | Dec 2027 |
| NCT04855656 | Lunresertib | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT04855656 | RP-3500 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT04855656 | Zedoresertib (Debio 0123) | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT06129539 | Debio 4326 | Phase 3 | Central Precocious Puberty | Metabolic and endocrine | Feb 2028 |
| NCT06930625 | Debio 4126 | Phase 3 | Acromegaly | Metabolic and endocrine | Jun 2028 |
| NCT05765812 | Zedoresertib (Debio 0123) | Phase 1 | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Oncology | Sep 2028 |
| NCT06969430 | Debio 1562M | Phase 1 | Acute Myeloid Leukemia | Oncology | Nov 2031 |
Crinetics Pharmaceuticals Kyowa Kirin RayzeBio Shandong Boan Biotechnology Nuvalent
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.